Category 3 - THERAPEUTIC PROCEDURES
16018 - Additional Information
Item Start Date:
01-May-2000
Description Updated:
01-Jul-2023
Schedule Fee Updated:
01-Nov-2023
Group
T3 - Therapeutic Nuclear Medicine
Administration of 153 Sm-lexidronam for the relief of bone pain due to skeletal metastases (as indicated by a positive bone scan), if systemic antineoplastic therapy is unavailable or has failed to control the patient’s disease, and:
a) the disease is poorly controlled by conventional radiotherapy; or
b) conventional radiotherapy is inappropriate, due to the wide distribution of sites of bone pain.
Fee: $4,838.75 Benefit: 75% = $3,629.10 85% = $4,740.05
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change